A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

NCT03172494 · Completed

Last updated 2026-05-28

This trial compares three diabetes treatments—insulin degludec/liraglutide, insulin degludec alone, and liraglutide alone—in adults with type 2 diabetes whose blood sugar is not well controlled by oral medications.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 720 people

Who can join Ages 18+ · all sexes

Timeline Started 2017-05 · est. completion 2019-07

Where 36 sites · China

What this study is testing ClinicalTrials.gov NCT03172494 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Treatments tested

Insulin degludec/liraglutide Drug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
Insulin degludec Drug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
Liraglutide Drug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

Main thing measured	Change in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03172494 ↗